详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, China. [2]Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. [3]Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China. [4]Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.

出处：

DOI：

ISSN：

关键词： non-small cell lung cancer targeted therapy treatment response drug resistance tyrosine kinase inhibitor

摘要：

Lung cancer remains the leading cause of mortality worldwide. Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer with a generally poor prognosis. In recent years, advances in targeted therapy and sequencing technology have brought significant improvement in the therapeutic outcomes of patients with advanced NSCLC. Targeted inhibitors directed against specific mutated or rearranged oncogenes, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and receptor tyrosine kinase ROS proto-oncogene 1(ROS1) among others, exhibit promising anti-tumor activity. Unfortunately, some patients develop acquired resistance and disease progression soon after initial remission. Despite the continuous development of new drugs and strategies to overcome drug resistance, it is still a major challenge in the treatment of NSCLC. The landscape of targeted therapy for NSCLC is evolving rapidly in response to the pace of scientific research. This study aimed to provide a comprehensive review of tumor target antigens and agents related to targeted therapy in NSCLC.Copyright © 2024 Zhang, Zhang, Zhu, Dong and Liu.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

最新[2023]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

第一作者：

第一作者机构： [1]Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]ALK阳性非小细胞肺癌靶向治疗及其耐药机制的研究进展 [2]Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges [3]The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable [4]Cordycepin Inhibits Drug-resistance Non-small Cell Lung Cancer Progression by Activating AMPK Signaling Pathway. [5]Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer [6]Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated NSCLC. [7]Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy [8]Ficonalkib (SY-3505) in Advanced ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Open-Label, Single-Arm, Phase I/Ⅱ Study [9]A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study. [10]VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment